Literature DB >> 24166585

Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV-infected patients.

Yuria Ablanedo-Terrazas1, Claudia Alvarado-de la Barrera, Ramón Hernández-Juan, Matilde Ruiz-Cruz, Gustavo Reyes-Terán.   

Abstract

OBJECTIVES/HYPOTHESIS: The World Health Organization endorsed the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis (TB), but there is limited information about the utility of this assay for the diagnosis of TB lymphadenitis. Therefore, the objective of this study was to assess the diagnostic accuracy of Xpert MTB/RIF assay in HIV-infected patients with palpable cervical lymph nodes. STUDY
DESIGN: Prospective, diagnostic test study.
METHODS: Consecutive patients with cervical lymphadenopathy were prospectively enrolled between January 2011 and March 2013. Lymph node specimens were obtained through fine-needle aspiration or excisional biopsy. Mycobacterial culture was considered as the gold standard.
RESULTS: Mycobacterium TB was cultured from 15 of 68 specimens (22.05%), and 53 specimens had negative cultures (77.94%). The sensitivity of Xpert MTB/RIF was 100% (95% CI, 74.65%-100%), and the specificity was 100% (95% CI, 91.58%-100%). Smear microscopy had a lower diagnostic performance.
CONCLUSION: Although based on a limited sample size, our study indicates that Xpert MTB/RIF is a useful method for the diagnosis of cervical TB lymphadenitis in HIV-infected patients, regardless of the bacillary load in smear-positive samples or the CD4 T cell count. The sensitivity, specificity, positive predictive value, and negative predictive value were similar to gold-standard culture. LEVEL OF EVIDENCE: N/A.
© 2013 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  HIV; Xpert MTB/RIF; cervical lymphadenitis; extrapulmonary tuberculosis; lymph node tuberculosis

Mesh:

Substances:

Year:  2013        PMID: 24166585     DOI: 10.1002/lary.24478

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

Review 2.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

3.  Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in europe.

Authors:  Marc Tebruegge; Nicole Ritz; Karsten Koetz; Antoni Noguera-Julian; James A Seddon; Steven B Welch; Maria Tsolia; Beate Kampmann
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

4.  Epidemiology and diagnosis of tuberculous lymphadenitis in a tuberculosis low-burden country.

Authors:  Fernando Salvador; Ibai Los-Arcos; Adrián Sánchez-Montalvá; Teresa Tórtola; Adrian Curran; Ana Villar; Nuria Saborit; Josep Castellví; Israel Molina
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

5.  Evaluation of Xpert MTB/RIF for the Diagnosis of Lymphatic Tuberculosis.

Authors:  Hou-He Li; Zhi-Jian He; Jia-Qi Liang; Gui-Lin Li; Tian-Ao Xie; Ye-Ling Liu; Zhong-Wei Li; Xuan-Cheng Feng; Yong Xia; Xu-Guang Guo
Journal:  Biomed Res Int       Date:  2020-06-28       Impact factor: 3.411

Review 6.  Diagnostic Accuracy of the Xpert MTB/RIF Assay for Lymph Node Tuberculosis: A Systematic Review and Meta-Analysis.

Authors:  Guocan Yu; Fangming Zhong; Bo Ye; Xudong Xu; Da Chen; Yanqin Shen
Journal:  Biomed Res Int       Date:  2019-05-19       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.